Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel

International Journal of Pharmaceutics

Volumn 379, Issue 1-2, 2009, Pages 174-180

  Yanasarn, Nijaporn ^a   Sloat, Brian R ^a   Cui, Zhengrong ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

Biocompatibility; Cell uptake; Cytotoxicity; Emulsions; Nanoparticles

Indexed keywords

DOCETAXEL; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLYINOSINIC POLYCYTIDYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; BIOCOMPATIBILITY; CANCER CELL CULTURE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; DRUG TRANSPORT; FEMALE; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MOUSE; NANOEMULSION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SUSPENSION; THROMBOCYTE AGGREGATION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; DRUG STORAGE; EMULSIONS; FEMALE; HUMANS; LECITHINS; LIVER; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; TAXOIDS; WATER;

EID: 68649111125     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.06.004     Document Type: Article

References (24)

1. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2 (2002) 750-763
2. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
3. Clarke S.J., and Rivory L.P. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 36 (1999) 99-114
4. Cui Z., and Mumper R.J. Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm. Res. 19 (2002) 939-946
5. Cui Z., et al. Lecithin-based cationic nanoparticles as a potential DNA delivery system. Int. J. Pharm. 313 (2006) 206-213
6. De Jong W.H., and Borm P.J. Drug delivery and nanoparticles:applications and hazards. Int. J. Nanomed. 3 (2008) 133-149
7. Emerich D.F., and Thanos C.G. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol. Eng. 23 (2006) 171-184
8. Gabizon A., et al. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42 (2003) 419-436
9. Hwang H.Y., et al. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J. Controlled Release 128 (2008) 23-31
10. Immordino M.L., et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Controlled Release 91 (2003) 417-429
11. Jabr-Milane L.S., et al. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 34 (2008) 592-602
12. Jimenez M.A., et al. Evidence that polyunsaturated lecithin induces a reduction in plasma cholesterol level and favorable changes in lipoprotein composition in hypercholesterolemic rats. J. Nutr. 120 (1990) 659-667
13. Koziara J.M., et al. Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res. 22 (2005) 1821-1828
14. Le U.M., et al. Tumor chemo-immunotherapy using gemcitabine and a synthetic dsRNA. Cancer Biol. Ther. 7 (2008) 440-447
15. Liu B., et al. The antitumor effect of novel docetaxel-loaded thermosensitive micelles. Eur. J. Pharm. Biopharm. 69 (2008) 527-534
16. Lixin W., et al. A less irritant norcantharidin lipid microspheres: formulation and drug distribution. Int. J. Pharm. 323 (2006) 161-167
17. Oyewumi M.O., et al. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Controlled Release 95 (2004) 613-626
18. Ritger P.L., and Peppas N.A. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J. Controlled Release 5 (1987) 37-42
19. ten Tije A.J., et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 42 (2003) 665-685
20. Wade A., and Weller P.J. Handbook of Pharmaceutical Excipients (1994), American Pharmaceutical Association and The Pharmaceutical Press
21. Williams K.J., et al. Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle. Perspect. Biol. Med. 27 (1984) 417-431
22. Xu Z., et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30 (2009) 226-232
23. Yang L., et al. Inhibitory effects of beraprost on platelet aggregation: comparative study utilizing two methods of aggregometry. Thromb. Res. 94 (1999) 25-32
24. Zbinden G., et al. Assessment of thrombogenic potential of liposomes. Toxicology 54 (1989) 273-280